JAZZ News and Press, Jazz Pharmaceuticals plc From 02/23/21

Jazz Pharmaceuticals plc (JAZZ) Q4 2020 Earnings Conference Call February 23, 2021 04:30 PM ET Company Participants Andrea Flynn - Head of Investor Relations Bruce Cozadd - Chief Executive Officer Renée Galá - Chief Financial Officer Dan Swisher - President Rob Iannone - Executive V...

The following slide deck was published by Jazz Pharmaceuticals plc in conjunction with their 2020 Q4 earnings call. For further details see: Jazz Pharmaceuticals plc 2020 Q4 - Results - Earnings Call Presentation

Jazz Pharmaceuticals (JAZZ) reported Q4 EPS that missed analyst estimates by $0.20, though revenue beat by nearly $26.7M.Product sales of Xywav, a nacrolepsy drug that launched in November, in the quarter were $15.3M.At the end of Q4, there were 1,900 patients on Xywav, which has 92% les...

Jazz Pharmaceuticals Announces Participation at Cowen 41st Annual Healthcare Conference PR Newswire DUBLIN , Feb. 23, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentation at the...

Jazz Pharmaceuticals (JAZZ): Q4 Non-GAAP EPS of $4.00 misses by $0.20; GAAP EPS of $2.33 misses by $0.85.Revenue of $666.52M (+14.6% Y/Y) beats by $26.69M.2021 Full Year Total Revenue Guidance of $2.55 Billion to $2.70 Billion vs. $2.55B consensus.Press Release For further details see: ...

Jazz Pharmaceuticals Announces Full Year And Fourth Quarter 2020 Financial Results Highly Effective Operational Execution Drove Record Total Revenues Total Revenues Increased 9% to $2.36 Billion in 2020 2021 Full Year Total Revenue Guidance of $2.55 Billion to $2.70 Bill...

Jazz Pharmaceuticals Announces Participation in the Leerink 10th Annual Global Healthcare Conference PR Newswire DUBLIN , Feb. 17, 2021 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the company will webcast its corporate presentatio...

In the first marijuana industry buyout of 2021, Jazz Pharmaceuticals (NASDAQ: JAZZ) agreed to pay a hefty $7.6 billion to acquire GW Pharmaceuticals (NASDAQ: GWPH) , a developer of cannabis-based medications. Will their fortunes suddenly change if the U.S. fully legalize...

Jazz Pharmaceuticals (JAZZ) announces the completion of the rolling submission for the supplemental New Drug Application ((sNDA)) to the U.S. FDA for the marketing approval of Xywav oral solution for the treatment of adult patients with idiopathic hypersomnia.Xywav received Fast Tra...

Jazz Pharmaceuticals Completes Submission of Supplemental New Drug Application for Xywav™ (calcium, magnesium, potassium, and sodium oxybates) Oral Solution for Idiopathic Hypersomnia PR Newswire DUBLIN , Feb. 16, 2021 /PRNewswire/ -- Jazz Pharmaceuti...